Drug Type ASO |
Synonyms- |
Target |
Mechanism UBE3A inhibitors(ubiquitin protein ligase E3A inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Neurodevelopmental Disorders | Preclinical | US | 19 Apr 2024 |